BIOLOGIC
Epysqli (eculizumab-aagh) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating adults with paroxysmal nocturnal hemoglobinuria (PNH).
Epysqli (eculizumab-aagh) is biosimilar to eculizumab. This means it is designed to work like the original medicine and be used interchangeably. The FDA requires biosimilars to have no meaningful differences in safety or how well they work.
Epysqli is a type of medicine called a complement inhibitor. It works by blocking a protein called C5, which is part of the immune system. This helps prevent the formation of the terminal complement complex, a group of proteins that can cause red blood cells to break apart. In people with PNH, Epysqli helps reduce hemolysis, which is the breakdown of red blood cells.
Doctors prescribe Epysqli when an adult has PNH and needs treatment to reduce hemolysis.
Epysqli is given through a vein as an intravenous (IV) infusion, typically weekly for the first five weeks and then every two weeks. It is given by a healthcare provider.
The recommended starting dose of Epysqli for PNH is 600 milligrams weekly for the first four weeks, followed by 900 milligrams for the fifth dose one week later.
For adults who respond to treatment, the recommended maintenance dose is 900 milligrams every two weeks thereafter.
This information is based on the prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
In clinical studies of Epysqli for PNH in adults, the most common side effects occurred in about 16 percent to 44 percent of people. They include:
Epysqli has a boxed warning for serious meningococcal infections. Epysqli can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction or side effect.
This drug has a boxed warning, the FDA's strongest safety warning, for some of the serious risks mentioned above. A boxed warning does not mean the drug is unsafe for everyone or that everyone faces the same level of risk.
If you experience serious side effects, you can report them to the FDA online or by calling 1-800-FDA-1088. You can also contact the drug's manufacturer.
Teva Pharmaceuticals, Inc., the manufacturer of Epysqli, offers Epysqli Savings Program. Eligible people with commercial insurance may pay as little as $0.
To learn more, visit the Epysqli Savings Program website or call 844-478-1644.
You must be vaccinated against meningococcal infection (serogroups A, C, W, Y, and B) before starting Epysqli. If Epysqli must be started right away and you are not up to date on these vaccines, you should receive the vaccines as soon as possible and also take antibiotics as prescribed.
Tell your doctor if you have any allergies to eculizumab-aagh or any ingredients in Epysqli.
Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, and supplements.
Before you receive Epysqli, tell your healthcare provider about all of your medical conditions, including if you have an infection or fever.
Do not take Epysqli if you have an unresolved serious meningococcal (Neisseria meningitidis) infection.
If you are pregnant, planning to become pregnant, or breastfeeding while taking Epysqli, talk with your doctor about the risks and benefits.
Epysqli is also FDA-approved to treat atypical hemolytic uremic syndrome, generalized myasthenia gravis (in adults who are anti-acetylcholine receptor antibody positive), and neuromyelitis optica spectrum disorder (in adults who are anti-aquaporin-4 antibody positive).
These answers are fact-checked by our editorial staff.
How effective is Epysqli?
In a 26-week study of adults with PNH, 49 percent of people treated with eculizumab had stable hemoglobin levels without needing blood transfusions, compared with 0 percent receiving placebo. By week 1, the average level of lactate dehydrogenase (LDH), a marker of red blood cell breakdown, dropped from 2,200 units per liter before treatment to 700 units per liter. This reduction continued through week 26, when the average LDH level was 327 units per liter.
How long does Epysqli take to work for PNH?
In a clinical study of people with PNH, LDH levels dropped by week 1 of treatment with eculizumab. This reduction continued through week 26. People treated with eculizumab also reported less fatigue after three weeks of treatment.
Should I take Epysqli for PNH if I have an infection?
Epysqli should not be started if you have an unresolved serious meningococcal infection. It can raise the risk of serious infections, especially meningococcal infection, even in people who have been vaccinated.
Watch for symptoms such as fever, headache with nausea or vomiting, headache with a stiff neck or stiff back, confusion, muscle aches with flu-like symptoms, or eyes sensitive to light. Get medical care right away if you have any of these symptoms.
What should I do if I miss a dose of Epysqli for PNH?
If you miss an Epysqli infusion, call your healthcare provider right away. Epysqli should be given on the recommended schedule or within two days of the scheduled dose.
On myPNHteam, people share their experiences with paroxysmal nocturnal hemoglobinuria, get advice, and find support from others who understand.
Learn more about Epysqli and paroxysmal nocturnal hemoglobinuria care:
More resources from myPNHteam that mention Epysqli
Become a member to get even more